Isaralgagene civaparvovec is under clinical development by Sangamo Therapeutics and currently in Phase II for Fabry Disease. According to GlobalData, Phase II drugs for Fabry Disease have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Isaralgagene civaparvovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Isaralgagene civaparvovec overview
Isaralgagene civaparvovec (ST-920) is under development for the treatment of Fabry disease. The therapeutic candidate is a gene therapy that comprises recombinant adeno-associated virus vector serotype 2/6 (AAV2/6) encoding a human alpha-galactosidase A cDNA expressing galactosidase alpha (GLA) enzyme gene. It is formulated as solution and administered through intravenous route. It is developed based on the zinc finger protein (ZFP) Technology.
See Also:
Sangamo Therapeutics overview
Sangamo Therapeutics (Sangamo), formerly Sangamo BioSciences, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Huntington’s disease, Fabry disease, Alzheimer’s disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.
For a complete picture of Isaralgagene civaparvovec’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
